IQVIA Holdings has recently seen its consensus analyst price target rise significantly, climbing from $223.42 to $246.84.

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug ...

Steve will be monitoring the Rapid Fires: AI/ML in Bioanalysis session on Monday, Nov. 10, 2025 at 3PM CT at AAPS PharmSci ...

On November 5, 2025, IQVIA Holdings Inc. announced the appointment of Dr. William G. Kaelin Jr. to its Board of Directors. Dr. Kaelin, a Nobel Prize-winning scientist with extensive expertise in ...

Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.

Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services.

IQVIA Holdings has seen its consensus analyst price target rise slightly to $223 from $218, reflecting a modest uptick in projected fair value. Analysts link this change to confidence in the company's ...

IQVIA's third quarter results reflected stable operational execution, with revenue and profit slightly ahead of Wall Street expectations. Management identified robust free cash flow generation and a ...

Oakmark spotlights six stocks driving AI, M&A, and analytics upside, while navigating debt, guidance cuts, and valuation ...

Get key takeaways from IQVIA’s record Q3 2025—strong bookings, free cash flow, AI momentum, and guidance reaffirmed.

See Agentic AI in action as it eases site payments manual processes such as Clinical Trial Agreements (CTAs) ingestion and ...

IQVIA reaffirmed its full-year 2025 guidance, narrowing the ranges to revenue between $16.15 billion and $16.25 billion and adjusted earnings per share between $11.85 and $11.95, in line with analyst ...